Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

Related Keywords

,Ohio State University Comprehensive Cancer Center ,Division Of Urologic Oncology ,Ohio State University Wexner Medical Center ,Urologic Oncology ,Bacillus Calmette Gu ,Pembrolizumab Monotherapy ,Erica Singer ,D ,Bacillus Calmette Guérin Bcg Unresponsive ,High Risk Non Muscle Invasive Bladder Cancer ,